Descrição

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 bilhão durante 2021-2027, crescendo a uma taxa composta de crescimento anual (CAGR) de 8.6% durante o período de previsão, de acordo com a empresa de dados e análise StrategyHelix. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2017-2020 e previsão para 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, tecnologia, age, analysis target, and region. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. By technology, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, e outros. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
Tecnologia: polymerase chain reaction (PCR), next-generation sequencing, microarrays, e outros
Age: children, and adult
Região: América do Norte, Ásia-Pacífico, Europa, and Rest of the World (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
Anos considerados: este relatório cobre o período 2017 para 2027

Principais benefícios para as partes interessadas

Get a comprehensive picture of the global rare disease diagnostics market
Identificar estratégias regionais e prioridades estratégicas com base em dados e análises locais
Identifique setores de crescimento e tendências para investimento
Understand what the future of the global rare disease diagnostics market looks like
Identifique o cenário competitivo e a janela de oportunidade

Índice

1. Definição de mercado
2. Metodologia de Pesquisa
3. Dados de mercado & Panorama
3.1 Valor de mercado
3.2 Previsão de valor de mercado
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 Outros
6. Rare Disease Diagnostics Market by Age
6.1 Crianças
6.2 Adulto
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 América do Norte
8.2 Ásia-Pacífico
8.3 Europa
8.4 Rest Of The World (Row)
9. Perfis de empresa
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, Inc..
9.10 Quest Diagnostics Incorporated
10. Apêndice
10.1 Sobre StrategyHelix
10.2 Isenção de responsabilidade